New hope for kidney disease: BHV-1400 trial targets protein leak
NCT ID NCT07642050
First seen Jun 12, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study tests whether BHV-1400 can safely reduce kidney damage in people with IgA nephropathy, a disease where antibodies build up in the kidneys. About 420 adults with confirmed IgA nephropathy and high protein in their urine will be randomly assigned to receive either BHV-1400 or a placebo. The main goal is to see if the drug lowers protein levels in urine after one year, which would suggest better kidney health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.